Multiple Suitors Could Be Looking to Buy Genzyme

Rumors are that Sanofi has proposed to buy Genzyme for $70 a share. But Sanofi isn't the only one looking to deal. Analysts believe the likes of Pfizer and the U.K. 's GlaxoSmithKline have expressed an interest, as well. And others could be considering a bid also.